These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23980075)

  • 21. Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia.
    Bardeesy N; Morgan J; Sinha M; Signoretti S; Srivastava S; Loda M; Merlino G; DePinho RA
    Mol Cell Biol; 2002 Jan; 22(2):635-43. PubMed ID: 11756558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation.
    Robinson JP; VanBrocklin MW; Guilbeault AR; Signorelli DL; Brandner S; Holmen SL
    Oncogene; 2010 Jan; 29(3):335-44. PubMed ID: 19855433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bmi1 is required for the initiation of pancreatic cancer through an Ink4a-independent mechanism.
    Bednar F; Schofield HK; Collins MA; Yan W; Zhang Y; Shyam N; Eberle JA; Almada LL; Olive KP; Bardeesy N; Fernandez-Zapico ME; Nakada D; Simeone DM; Morrison SJ; Pasca di Magliano M
    Carcinogenesis; 2015 Jul; 36(7):730-8. PubMed ID: 25939753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas.
    Vincent DF; Yan KP; Treilleux I; Gay F; Arfi V; Kaniewski B; Marie JC; Lepinasse F; Martel S; Goddard-Leon S; Iovanna JL; Dubus P; Garcia S; Puisieux A; Rimokh R; Bardeesy N; Scoazec JY; Losson R; Bartholin L
    PLoS Genet; 2009 Jul; 5(7):e1000575. PubMed ID: 19629168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network.
    Ying H; Elpek KG; Vinjamoori A; Zimmerman SM; Chu GC; Yan H; Fletcher-Sananikone E; Zhang H; Liu Y; Wang W; Ren X; Zheng H; Kimmelman AC; Paik JH; Lim C; Perry SR; Jiang S; Malinn B; Protopopov A; Colla S; Xiao Y; Hezel AF; Bardeesy N; Turley SJ; Wang YA; Chin L; Thayer SP; DePinho RA
    Cancer Discov; 2011 Jul; 1(2):158-69. PubMed ID: 21984975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression.
    Albury TM; Pandey V; Gitto SB; Dominguez L; Spinel LP; Talarchek J; Klein-Szanto AJ; Testa JR; Altomare DA
    Neoplasia; 2015 Feb; 17(2):175-82. PubMed ID: 25748236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
    Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
    Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. E-cadherin expression in obesity-associated, Kras-initiated pancreatic ductal adenocarcinoma in mice.
    Stark AP; Chang HH; Jung X; Moro A; Hertzer K; Xu M; Schmidt A; Hines OJ; Eibl G
    Surgery; 2015 Dec; 158(6):1564-72. PubMed ID: 26297056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells.
    Lee KE; Bar-Sagi D
    Cancer Cell; 2010 Nov; 18(5):448-58. PubMed ID: 21075310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose-dependent effects of calorie restriction on gene expression, metabolism, and tumor progression are partially mediated by insulin-like growth factor-1.
    Nogueira LM; Lavigne JA; Chandramouli GV; Lui H; Barrett JC; Hursting SD
    Cancer Med; 2012 Oct; 1(2):275-88. PubMed ID: 23342276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling.
    Gruber R; Panayiotou R; Nye E; Spencer-Dene B; Stamp G; Behrens A
    Gastroenterology; 2016 Sep; 151(3):526-39. PubMed ID: 27215660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heparin-binding epidermal growth factor-like growth factor eliminates constraints on activated Kras to promote rapid onset of pancreatic neoplasia.
    Ray KC; Moss ME; Franklin JL; Weaver CJ; Higginbotham J; Song Y; Revetta FL; Blaine SA; Bridges LR; Guess KE; Coffey RJ; Crawford HC; Washington MK; Means AL
    Oncogene; 2014 Feb; 33(7):823-31. PubMed ID: 23376846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer.
    Bardeesy N; Cheng KH; Berger JH; Chu GC; Pahler J; Olson P; Hezel AF; Horner J; Lauwers GY; Hanahan D; DePinho RA
    Genes Dev; 2006 Nov; 20(22):3130-46. PubMed ID: 17114584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucose metabolism during tumorigenesis in the genetic mouse model of pancreatic cancer.
    Pasquale V; Dugnani E; Liberati D; Marra P; Citro A; Canu T; Policardi M; Valla L; Esposito A; Piemonti L
    Acta Diabetol; 2019 Sep; 56(9):1013-1022. PubMed ID: 30989379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia.
    Shi G; DiRenzo D; Qu C; Barney D; Miley D; Konieczny SF
    Oncogene; 2013 Apr; 32(15):1950-8. PubMed ID: 22665051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CDKN2B deletion is essential for pancreatic cancer development instead of unmeaningful co-deletion due to juxtaposition to CDKN2A.
    Tu Q; Hao J; Zhou X; Yan L; Dai H; Sun B; Yang D; An S; Lv L; Jiao B; Chen C; Lai R; Shi P; Zhao X
    Oncogene; 2018 Jan; 37(1):128-138. PubMed ID: 28892048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Critical role of oncogenic KRAS in pancreatic cancer (Review).
    Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
    Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ink4a/Arf loss promotes tumor recurrence following Ras inhibition.
    Vanbrocklin MW; Robinson JP; Lastwika KJ; McKinney AJ; Gach HM; Holmen SL
    Neuro Oncol; 2012 Jan; 14(1):34-42. PubMed ID: 22015595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
    Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
    Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis.
    Whipple CA; Young AL; Korc M
    Oncogene; 2012 May; 31(20):2535-44. PubMed ID: 21996748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.